Search

Your search keyword '"Imai, Masaki"' showing total 666 results

Search Constraints

Start Over You searched for: Author "Imai, Masaki" Remove constraint Author: "Imai, Masaki"
666 results on '"Imai, Masaki"'

Search Results

53. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques

55. The trajectory of non‐depressed suicidal ideation in community‐dwelling older people in a rural area in Japan: a prospective longitudinal study with a 3‐year follow‐up

58. Characterization of a Feline Influenza A(H7N2) Virus

59. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo

60. Peritoneal Expression of Membrane Complement Regulators Is Decreased in Peritoneal Dialysis Patients with Infected Peritonitis

61. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate

62. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

64. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1

65. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

66. SARS-CoV-2 Transmission from Virus-Infected Dead Hamsters

68. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer

69. Avian H7N9 influenza viruses are evolutionarily constrained by stochastic processes during replication and transmission in mammals

70. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

72. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

73. Magnetic Phases in Sr1-x CaxCo2P2 Studied by μ+ SR

76. Long-term peritoneal dialysate exposure modulates expression of membrane complement regulators in human peritoneal mesothelial cells

77. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

78. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75

79. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.

80. Temperature-variable apparatus for measuring Barnett field.

82. Can SARS-CoV-2 transmit from a dead body?

83. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

84. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant

85. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

86. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 clinical isolates

87. Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.

89. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

90. Pressure driven magnetic order in Sr1-xCaxCo2P2

91. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

92. Avian H7N9 influenza viruses are evolutionarily constrained by stochastic processes during replication and transmission in mammals

94. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

96. Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine

97. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

98. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

99. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

Catalog

Books, media, physical & digital resources